Biologics have higher psoriatic arthritis adherence

Share this article:

Step therapy is a familiar cost-control measure in which payers have patients test out lower-price medications before granting approval for higher-priced ones, in the hope that cheaper interventions can achieve the same goal.

A study published in Arthritis Research & Therapy and reported on by Medpage Today indicates that this approach may have a downside among psoriatic arthritis patients. The study found that patients were more likely to stop taking their psoriatic arthritis medication if non-biologics were their first treatment, but were more likely to stick with a treatment regimen if biologics were their first prescription experience.

The retrospective analysis of insurance claims could not determine why patients stopped their medications, but researchers did find that 79% of patients taking an oral non-biologic disease-modifying anti-rheumatic drug stopped the drug prescribed, 25% switched and 30% added on a treatment. In contrast, patients who started on biologics had a 92% adherence rate after one month, 80% after three months and 54% stuck with therapy after a year.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.